SDHB Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SDHB Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SDHB</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SDHB</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=SDHB" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/kidney-cancer" style="color:#ef9a9a">Kidney Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">36 edges</a></td>
</tr>
</table>
SDHB (succinate dehydrogenase iron-sulfur subunit B) is a core catalytic component of mitochondrial Complex II, a unique respiratory complex that also functions as an enzyme of the tricarboxylic acid (TCA) cycle. By linking succinate oxidation to electron transfer into the ubiquinone pool, SDHB sits at a critical metabolic checkpoint for neuronal energy production, redox control, and signaling. Although SDHB is classically discussed in tumor predisposition syndromes, Complex II stress and succinate-driven signaling have growing relevance to neurodegeneration mechanisms.
Structure And Core Function
Complex II is composed of SDHA/SDHB catalytic subunits and SDHC/SDHD membrane anchors. SDHB carries iron-sulfur clusters that relay electrons from SDHA (succinate oxidation) toward membrane-bound ubiquinone reduction.[@sun2005][@cecchini2003] This architecture makes SDHB essential for coupling the TCA cycle to respiratory-chain electron flow.
In [neurons](/entities/neurons) and glia, SDHB integrity supports:
- Mitochondrial ATP generation under sustained activity
- Efficient carbon flux through central metabolism
- Lower [ROS](/entities/reactive-oxygen-species) leak by preserving respiratory efficiency
When SDHB function declines, succinate can accumulate, respiratory output can drop, and oxidative stress plus inflammatory signaling can increase.[@lin2006][@selak2005]
Neurodegeneration-Relevant Biology
SDHB dysfunction intersects with several pathways important in chronic neurodegenerative disease:
Energetic inefficiency reducing ATP reserve for synaptic and axonal functions[@lin2006][@johri2012]
Succinate signaling effects that can stabilize hypoxia pathways and alter inflammatory tone[@selak2005][@gill2018]
Mitochondrial ROS amplification driving lipid/protein oxidation in vulnerable neuronal populations[@johri2012][@wang2010]
Metabolic-glial coupling defects that can compromise support for high-demand circuits in [cortex](/brain-regions/cortex) and basal ganglia[@lin2006][@johri2012]This framework connects SDHB/Complex II biology to broader mitochondrial dysfunction signatures seen in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and multisystem tauopathies where energetic reserve is limited.[@lin2006][@johri2012]
Human Genetics And Clinical Context
Pathogenic SDHB variants are well established in hereditary paraganglioma-pheochromocytoma syndromes, with disease risk linked to impaired succinate dehydrogenase function and pseudohypoxic signaling.[@gill2018][@fishbein2012] Primary neurodegenerative syndromes directly caused by SDHB are uncommon, but SDH pathway disruption offers a robust human model of mitochondrial-metabolic stress with CNS implications.[@selak2005][@fishbein2012]
In neurodegeneration research, SDHB is therefore relevant less as a single-disease marker and more as part of an integrated mitochondrial vulnerability network that includes Complex I deficits, altered NAD redox state, and impaired quality-control programs.[@lin2006][@wang2010]
Biomarker And Translational Opportunities
Potential SDHB-related readouts in translational studies include:
- Respiratory profiling with Complex II contributions in patient-derived cells[@sun2005][@cecchini2003]
- Metabolic signatures involving succinate/fumarate and downstream redox changes[@selak2005][@gill2018]
- Multimodal stress phenotyping (oxidative markers plus inflammation markers) for subgrouping[@johri2012][@wang2010]
These markers are most informative when interpreted in context with broader mitochondrial pathway features, rather than as isolated endpoints.
Therapeutic Strategy Landscape
There is no approved therapy that directly rescues SDHB-specific deficits in neurodegeneration. Current strategy is pathway-oriented:
- Mitochondrial support combinations under [mitochondrial neuroprotection](/therapeutics/mitochondrial-neuroprotection)[@johri2012]
- Respiratory chain support and redox buffering via [coenzyme Q10](/therapeutics/coenzyme-q10-neurodegeneration)-class interventions[@beal2005]
- Metabolic flexibility support through [NAD+ precursors](/therapeutics/nad-precursors-neurodegeneration) and exercise-centered programs[@lautrup2019]
Future precision approaches may require stratifying patients by integrated mitochondrial-metabolic phenotypes rather than single-gene status alone.
Open Research Questions
- How much Complex II reserve is required to prevent stress tipping points in specific neuronal populations?
- Which succinate-linked signals are causal versus compensatory in human neurodegeneration?
- Can combined metabolomic and respiratory profiling identify SDHB-relevant responder subgroups for mitochondrial therapies?
See Also
- [SDHB](/genes/sdhb)
- [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)
- [Mitochondrial Neuroprotection](/therapeutics/mitochondrial-neuroprotection)
- [Coenzyme Q10 and Neurodegeneration](/therapeutics/coenzyme-q10-neurodegeneration)
- [NAD+ Precursors for Neurodegeneration](/therapeutics/nad-precursors-neurodegeneration)
External Links
- [UniProt: sdhb](https://www.uniprot.org/)
- [PubMed: sdhb](https://pubmed.ncbi.nlm.nih.gov/?term=sdhb+neurodegeneration)
References
[Sun F, Huo X, Zhai Y, et al, Crystal structure of mitochondrial respiratory membrane protein complex II (2005)](https://doi.org/10.1016/j.cell.2005.05.025)
[Cecchini G, Function and structure of complex II of the respiratory chain (2003)](https://doi.org/10.1016/S0005-2728(03)
[Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)](https://doi.org/10.1038/nature05292)
[Selak MA, Armour SM, MacKenzie ED, et al, Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase (2005)](https://doi.org/10.1016/j.ccr.2005.07.022)
[Johri A, Beal MF, Mitochondrial dysfunction in neurodegenerative diseases (2012)](https://doi.org/10.1177/1759091411423216)
[Gill AJ, Succinate dehydrogenase (SDH)-deficient neoplasia (2018)](https://doi.org/10.1111/his.12533)
[Wang X, Michaelis EK, Selective neuronal vulnerability to oxidative stress in the brain (2010)](https://doi.org/10.1016/j.freeradbiomed.2010.07.001)
[Fishbein L, Nathanson KL, Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background (2012)](https://doi.org/10.1016/j.ctrv.2012.05.009)
[Beal MF, Mitochondria and neurodegeneration (2005)](https://doi.org/10.1016/j.neuron.2005.09.012)
[Lautrup S, Sinclair DA, Mattson MP, Fang EF, NAD+ in brain aging and neurodegenerative disorders (2019)](https://doi.org/10.1016/j.cmet.2019.06.001)